| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Silvia G Priori | |
| Nian Liu | |||
| Yanfei Ruan | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | catecholaminergic polymorphic ventricular tachycardia | Q1649897 |
| ventricular tachycardia | Q56002 | ||
| tachycardia | Q209583 | ||
| P304 | page(s) | 23-30 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Progress in Cardiovascular Diseases | Q2635289 |
| P1476 | title | Catecholaminergic polymorphic ventricular tachycardia | |
| P478 | volume | 51 |
| Q34979817 | A mathematical model of spontaneous calcium release in cardiac myocytes |
| Q36130339 | A mechanistic description of gating of the human cardiac ryanodine receptor in a regulated minimal environment |
| Q34575281 | Acute atrial arrhythmogenicity and altered Ca(2+) homeostasis in murine RyR2-P2328S hearts |
| Q37465870 | Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia. |
| Q39022381 | Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia |
| Q47298913 | An optogenetic arrhythmia model to study catecholaminergic polymorphic ventricular tachycardia mutations |
| Q36172467 | Behavioral influences on cardiac arrhythmias |
| Q42932530 | CPU228, a derivative of dofetilide, relieves cardiac dysfunction by normalizing FKBP12.6, NADPH oxidase and protein kinase C ε in the myocardium |
| Q92409590 | CPVT: Arrhythmogenesis, Therapeutic Management, and Future Perspectives. A Brief Review of the Literature |
| Q36913211 | Calcium Sparks in the Heart: Dynamics and Regulation |
| Q54644396 | Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia. |
| Q28262015 | Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia |
| Q37728178 | Cardiac Channelopathies and Sudden Death: Recent Clinical and Genetic Advances |
| Q36486478 | Cardiac ion channelopathies and the sudden infant death syndrome |
| Q36225404 | Cardiovascular health, part 2: sports participation in athletes with cardiovascular conditions |
| Q37463403 | Cardiovascular translational medicine (IV): The genetic basis of malignant arrhythmias and cardiomyopathies. |
| Q48254346 | Case of undiagnosed catecholaminergic polymorphic ventricular tachycardia presenting with ventricular fibrillation after administration of succinylcholine during anesthesia for modified electroconvulsive therapy. |
| Q26747056 | Catecholaminergic polymorphic ventricular tachycardia: An exciting new era |
| Q33157298 | Catecholaminergic polymorphic ventricular tachycardia: a current overview. |
| Q90170780 | Classification and correlation of RYR2 missense variants in individuals with catecholaminergic polymorphic ventricular tachycardia reveals phenotypic relationships |
| Q27021919 | Clinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem Cells |
| Q37305690 | Conformational dynamics inside amino-terminal disease hotspot of ryanodine receptor |
| Q93257610 | Distinct mechanisms mediate pacemaker dysfunction associated with catecholaminergic polymorphic ventricular tachycardia mutations: Insights from computational modeling |
| Q38602828 | Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin. |
| Q53490873 | Exon 3 deletion of ryanodine receptor causes left ventricular noncompaction, worsening catecholaminergic polymorphic ventricular tachycardia, and sudden cardiac arrest. |
| Q24312162 | FKBP12.6 binding of ryanodine receptors carrying mutations associated with arrhythmogenic cardiac disease |
| Q33160839 | Follow-up with exercise test of effort-induced ventricular arrhythmias linked to ryanodine receptor type 2 gene mutations |
| Q37749844 | Genetic basis of malignant channelopathies and ventricular fibrillation in the structurally normal heart |
| Q38118161 | Genetic etiology and evaluation of sudden cardiac death |
| Q43182612 | High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening |
| Q26750618 | Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Afford New Opportunities in Inherited Cardiovascular Disease Modeling |
| Q39050993 | Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening |
| Q36667578 | In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia. |
| Q37005193 | In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells |
| Q52679005 | Ion Channel Disorders and Sudden Cardiac Death. |
| Q33163102 | Modeling Catecholaminergic Polymorphic Ventricular Tachycardia using Induced Pluripotent Stem Cell-derived Cardiomyocytes |
| Q36526379 | Modeling a ryanodine receptor N-terminal domain connecting the central vestibule and the corner clamp region |
| Q39038606 | Murine Electrophysiological Models of Cardiac Arrhythmogenesis |
| Q24300356 | Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death |
| Q47174155 | Neonatal arrhythmias: diagnosis, treatment, and clinical outcome |
| Q33161429 | Paradoxical effect of increased diastolic Ca(2+) release and decreased sinoatrial node activity in a mouse model of catecholaminergic polymorphic ventricular tachycardia. |
| Q50700554 | Post-natal heart adaptation in a knock-in mouse model of calsequestrin 2-linked recessive catecholaminergic polymorphic ventricular tachycardia. |
| Q39163186 | Postexertional supraventricular tachycardia in children with catecholaminergic polymorphic ventricular tachycardia |
| Q50977982 | Postmortem genetic testing of the ryanodine receptor 2 (RYR2) gene in a cohort of sudden unexplained death cases. |
| Q30498471 | Prevention of Ventricular Arrhythmia and Calcium Dysregulation in a Catecholaminergic Polymorphic Ventricular Tachycardia Mouse Model Carrying Calsequestrin-2 Mutation |
| Q34094086 | Purkinje cells from RyR2 mutant mice are highly arrhythmogenic but responsive to targeted therapy |
| Q33159915 | Recent developments in the management of patients at risk for sudden cardiac death. |
| Q33158864 | Risk stratification in young patients with channelopathies. |
| Q44731788 | Role of coupled gating between cardiac ryanodine receptors in the genesis of triggered arrhythmias |
| Q64074155 | The Brazilian Society of Cardiology and Brazilian Society of Exercise and Sports Medicine Updated Guidelines for Sports and Exercise Cardiology - 2019 |
| Q43196379 | The differential diagnosis of primary electrical diseases from seizures in childhood |
| Q35940357 | The effect of K201 on isolated working rabbit heart mechanical function during pharmacologically induced Ca2+ overload. |
| Q43635606 | The future of sudden cardiac death. |
| Q33162743 | The role of ion channelopathies in sudden cardiac death: implications for clinical practice |
| Q35806084 | Translating advances in cardiogenetics into effective clinical practice. |
| Q36786528 | Triadin regulates cardiac muscle couplon structure and microdomain Ca(2+) signalling: a path towards ventricular arrhythmias |
| Q26801317 | Triadin regulation of the ryanodine receptor complex |
| Q87809814 | Yield of the RYR2 Genetic Test in Suspected Catecholaminergic Polymorphic Ventricular Tachycardia and Implications for Test Interpretation |
Search more.